Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life-threatening diseases. The company is headquartered in Hayward, California and currently employs 21 full-time employees. The company went IPO on 2010-03-02. The firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
Follow-Up Questions
Anthera Pharmaceuticals Inc のCEOは誰ですか？
Mr. J. Craig Thompson は Anthera Pharmaceuticals Inc の President で、2016 から在籍しています。
ANTH の株価パフォーマンスは？
ANTH の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Anthera Pharmaceuticals Inc の主な事業テーマや業界は？
Anthera Pharmaceuticals Inc は Biotechnology 業界、セクターは Health Care に属しています。
